Effects of lipid-lowering treatment on platelet reactivity and plateletleukocyte aggregation in diabetic patients without and with chronic kidney disease: A randomized trial

Abstract

Background. Diabetes mellitus (DM) is associated with hyperreactive platelets and increased plateletleukocyte aggregation (PLA), but the impact of concomitant chronic kidney disease (CKD) has been much less studied. Lipid-lowering treatment (LLT) may have favorable effects on platelet activation and inflammation. The objective of this mechanistic study was to investigate the impact of CKD on platelet function and inflammatory parameters in patients with DM and the effects of LLT. Methods. After a placebo run-in period, the effects of simvastatin alone (S) or simvastatin ezetimibe (S E) were compared in a randomized, double-blind, cross-over study on platelet reactivity, PLA formation and inflammatory parameters. Eighteen DM patients with estimated glomerular filtration rate (eGFR) 1559 mL/min × 1.73 m2 (CKD stages 34) (DM-CKD) and 21 DM patients with eGFR >75 mL/min (DM-only) were included. Results. PLAs were elevated at baseline in DM-CKD compared with DM-only (P = 0.04). S E reduced PLAs among total leukocytes and neutrophils in DM-CKD patients (P = 0.01 for both) but not in the DM-only group. Platelet reactivity did not differ between patient groups or with LLT. Plasma levels of sCD40L (P < 0.001), elastase (P < 0.01) and von Willebrand factor (VWF) (P < 0.001) were elevated in DM-CKD compared with DM-only. S E reduced sCD40L in DM-CKD patients (P = 0.01), but LLT did not influence VWF or elastase. Conclusions. DM patients with CKD stages 34 had increased PLA and inflammatory activity compared with DM patients with normal GFR. Simvastatin ezetimbe decreased PLAs and plasma sCD40L in DM patients with concomitant CKD. Clinical Trial registrationhttp://www.clinicaltrials.gov. Identifier NCT01035320. © 2012 The Author.